MMP2 and inflammatory breast carcinoma: This analysis showed for the first time to our knowledge that, in the HER2-positive IBC patient population of the BEVERLY-2 trial, baseline MMP2 and MMP9 serum levels are associated with DFS and OS, are anti-correlated, and significantly changed during bevacizumab- and trastuzumab-based neo-adjuvant chemotherapy.